Pfizer Inc. Gets FDA Green Signal For The First Drug To Treat A Rare Lung ...
Common adverse effects of the drug included mouth and lip ulcers, abdominal pain, diarrhea, sore throat, nausea, chest pain, headache, acne, muscle pain, respiratory infections, dizziness, and raised cholesterol. Major adverse reactions included ...
Bidness ETC - Fri, 29 May 2015 03:18

Rapamune becomes the 1st FDA approved drug to treat rare lung disease
Outbreak News Today - Thu, 28 May 2015 15:41

Pfizer's Rapamune Receives FDA Approval To Treat Rare Lung Disease
Immortal News - Thu, 28 May 2015 20:11

FDA approves Rapamune to treat LAM, a very rare lung disease
EIN News (press release) - Thu, 28 May 2015 13:15

US Food and Drug Administration Approves Humalog® 200 units/mL KwikPen®
Hypersensitivity Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with Humalog. If hypersensitivity reactions occur, discontinue Humalog and treat per standard of care until signs and symptoms resolve ...
MarketWatch - Wed, 27 May 2015 05:22



Neural Circuits Linked To Excessive Coughing Exposed By Herpes
Mazzone added that cough hypersensitivity is a debilitating symptom of more than 100 respiratory diseases, yet cough-suppressing treatments generally are not effective. Team member Dr. Alice McGovern said the research team co-opted a specific strain of ...
Asian Scientist Magazine - Tue, 26 May 2015 02:56

US Food and Drug Administration Approves Humalog 200 units/mL KwikPen
The FINANCIAL -- The U.S. Food and Drug Administration (FDA) has approved Humalog 200 units/mL KwikPen (insulin lispro 200 units/mL; U-200), a pre-filled pen containing a concentrated formulation of Lilly's rapid-acting insulin Humalog (insulin lispro ...
The FINANCIAL - Thu, 28 May 2015 01:48



FDA Okays Stiolto for COPD
WASHINGTON -- The FDA has approved once-daily tiotropium bromide and olodaterol (Stiolto Respimat) inhalation spray for maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), the drug's maker ...
MedPage Today - Tue, 26 May 2015 12:07

COPD Treatment Inhalation Spray Approved
MD Magazine - Tue, 26 May 2015 09:52

FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as ...
Virtual Press Office (press release) - Tue, 26 May 2015 05:00



Researchers make important breakthrough in identifying major drivers of ...
"The irritating sensations from the upper respiratory tract are a major driver of excessive coughing. "Cough hypersensitivity is a debilitating symptom of more than 100 respiratory diseases, yet cough-suppressing treatments generally don't work.".
News-Medical.net - Tue, 26 May 2015 22:47

Herpes Offers Big Insights on Coughing and Potential New Remedies
"The irritating sensations from the upper respiratory tract are a major driver of excessive coughing. Cough hypersensitivity is a debilitating symptom of more than 100 respiratory diseases, yet cough-suppressing treatments generally don't work." Team ...
Infection Control Today - Fri, 22 May 2015 07:03

SIMPONI® (golimumab) Gains Positive Opinion from Committee for Medicinal ...
In post-marketing experience, serious systemic hypersensitivity reactions (including anaphylactic reaction) have been reported following SIMPONI administration. Some of these reactions occurred after the first administration of ... The most common ...
Stockhouse - Tue, 26 May 2015 03:30


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014